SAN DIEGO, July 9 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA)
today announced the appointment of Stephen F. Flaim, Ph.D., F.A.C.C., to the
new position of Vice President of Biological Research and Development. Dr.
Flaim will direct all aspects of Trega's biology programs and report to Dr.
Lawrence Muschek, President of Research and Development.
"Steve has extensive experience in the biological aspects of drug
discovery and development," said Robert S. Whitehead, Trega's Chairman and
Chief Executive Officer. "His scientific stature, combined with his
leadership skills make Steve the right person to head our biology effort.
Steve will also allow us to maximize resources and opportunities created by
recent collaborations with Novartis and Ono Pharmaceuticals. In addition, he
will collaborate with Dr. Michael Green, Vice President of Chemistry, in
guiding Trega's technical platform and internal discovery programs."
Dr. Flaim will assume his new position effective today. Previously, he
was Vice President, Biological Sciences, at Alliance Pharmaceutical Corp.
Prior to that, Dr. Flaim worked in key research positions at the Squibb
Institute for Medical Research and McNeil Pharmaceuticals.
Trega Biosciences is a drug discovery company, utilizing combinatorial
chemistry and other technologies to pursue the discovery of novel, small-
molecule drug therapies. The company leverages its technology platform by
entering into pharmaceutical alliances, which provide partners with access to
Trega's technologies in exchange for licensing fees and potential milestones
and royalties, or by establishing joint-discovery alliances with
pharmaceutical and biotechnology companies. Trega also uses its drug
discovery technologies in its internal development programs, which are focused
today on discovering small molecules acting on melanocortin receptors.
Melanocortins are a class of receptors which may be important in the treatment
of inflammatory and metabolic diseases.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including whether the impending transition in
management will occur without disrupting the Company's business and
operations, whether any proposed product can be successfully formulated,
scaled-up, developed, and commercialized, whether regulatory approvals can be
obtained, the impact of competitive products and pricing, the financial
condition of the Company in the future, whether any corporate collaborations
or alliances will be successful, and other risks detailed from time to time in
Trega's Securities and Exchange Commission filings. These forward-looking
statements represent Trega's judgment as of the date of this release. Actual
results may differ materially from those projected. Trega disclaims, however,
any intent or obligation to update these forward-looking statements.
Trega's releases are on the World Wide Web at http://www.trega.com and PR
Newswire's fax-on-demand service at 1-800-758-5804, extension 374050.
SOURCE Trega Biosciences, Inc.
 back to top
Related links:
http://www.trega.com
Company News On-Call: http://www.prnewswire.com or
fax, 800-758-5804, ext. 374050
CONTACT:
Robert S. Whitehead, Chairman & CEO,
619-410-6631, or Vince Reardon, Director, Corporate
Communications, 619-410-6555, both of Trega Biosciences, Inc.
|
